Development asset linked to Jasper Therapeutics in public FDA and regional records.
biotech · Chronic Inducible Urticaria · Chronic Spontaneous Urticaria · JSPR
Jasper Therapeutics
Jasper Therapeutics drug portfolio — 13 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Redwood City, CA, US HQ
44 Employees
Public company Type
JSPR · NYSE Ticker
Company details
- Status
- Public
- HQ
- Redwood City, CA, US
- Employees
- 44
- Programs
- 13
- Drugs
- 13
- Patents
- 1
Jasper Therapeutics pipeline
Portfolio lens on 13 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Jasper Therapeutics drug portfolio — 13 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
Development asset linked to Jasper Therapeutics in public FDA and regional records.
-
epinephrine
Cardiovascular system (C01)US regulatory status: approved. Molecular target: Adrenergic receptor.
- Target
- Adrenergic receptor
- Mechanism
- Adrenergic receptor agonist
-
Development asset linked to Jasper Therapeutics in public FDA and regional records.
-
Development asset linked to Jasper Therapeutics in public FDA and regional records.
-
nelfinavir
Antiinfectives for systemic use (J05)Antiinfectives for systemic use (J05) compound in Jasper Therapeutics's portfolio.
-
US regulatory status: approved. Molecular target: Neuronal acetylcholine receptor; alpha4/beta2.
- Target
- Neuronal acetylcholine receptor; alpha4/beta2
- Mechanism
- Neuronal acetylcholine receptor; alpha4/beta2 agonist
-
US regulatory status: approved. Molecular target: Potassium-transporting ATPase.
- Target
- Potassium-transporting ATPase
- Mechanism
- Potassium-transporting ATPase inhibitor
-
US regulatory status: approved. Molecular target: Copper.
- Target
- Copper
- Mechanism
- Copper chelating agent
-
Development asset linked to Jasper Therapeutics in public FDA and regional records.
-
US regulatory status: approved.
-
US regulatory status: approved. Mechanism: Diagnostic agent.
- Mechanism
- Diagnostic agent
-
US regulatory status: approved. Molecular target: Bacterial penicillin-binding protein.
- Target
- Bacterial penicillin-binding protein
- Mechanism
- Bacterial penicillin-binding protein inhibitor